Bausch + Lomb (US:BLCO)2026-01-12 21:30Financial Targets (2025-2028) - The company projects a constant currency (CC) revenue compound annual growth rate (CAGR) of 5-7% from 2025 to 2028[15, 42] - The company anticipates an adjusted EBITDA margin (excluding Acquired IPR&D) of approximately 23% in 2028[15, 42] - The company aims for an adjusted cash flow from operations to adjusted EBITDA conversion of approximately 50% in 2028[37, 42] - The company targets a net leverage ratio of approximately 3.5x by the end of 2028[37, 42] - The company expects double-digit adjusted EPS growth from 2026 to 2028[37, 42] Pipeline and Product Launches - The company's pipeline products have potential peak sales of approximately $7 billion[15] - The company anticipates franchise peak sales of approximately $300 million for an advanced preservative-free lipid-based formulation launching in the first half of 2026[23] - The company anticipates franchise peak sales of approximately $600 million for products expanding the market by addressing all stages of AMD, launching in the first half of 2026[23] - The company anticipates franchise peak sales of approximately $450 million for enhanced comfort contact lens with the addition of hyaluronic acid, launching in 1H27[23] Consumer Brands - The company is the 1 global OTC eye health company with +7% last twelve months (LTM) constant currency revenue growth[22]